Danish Multicenter Study of Adalimumab in Spondyloarthritis
Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Spondyloarthropathies (SpA) are often diagnosed with a considerable delay (often 8-10 years
from symptom onset), because the available clinical, biochemical and radiological methods are
not sufficiently sensitive. TNF-a antagonists have recently been introduced for treatment of
SpA, and current data indicate a higher efficacy than previously available therapies. The
improved treatment options have increased the need for improved methods for diagnosis,
monitoring and prognostication of these diseases, so that the efficient therapies can be
initiated at the optimal time point and monitored optimally. Magnetic resonance imaging (MRI)
and a number of biomarkers are promising, but not yet sufficiently studied, methods for this.